Biogen Idec's Q1 profit falls on one-time charges and expiring Rituxan royalties
This article was originally published in Scrip
Executive Summary
Biogen Idec's first-quarter income fell by 11% to $217 million owing to one-time charges and the expiry of non-US royalties on the anti-CD20 monoclonal antibody Rituxan (rituximab), which is partnered with Roche. The company also reported only a "modest" increase in the number of patients taking its multiple sclerosis drug Tysabri (natalizumab) during January and February.